SCHEMBL23960332

SCHEMBL23960332

CN[C@H](Cc1ccc(O)cc1)C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.51
SLC7A5 Q01650 1/20 0.49
TAAR1 Q96RJ0 3/20 0.48
SLC6A2 P23975 1/20 0.48
FOLH1 Q04609 1/20 0.48
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA9 Q16790 1/20 0.47
ESR1 P03372 2/20 0.46
ESR2 Q92731 2/20 0.46
CA2 P00918 1/20 0.46
NAALAD2 Q9Y3Q0 1/20 0.44
LNPEP Q9UIQ6 1/20 0.44
MME P08473 1/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12118463 1.00 ACE (0.51) ACESLC7A5TAAR1SLC6A2FOLH1
SCHEMBL13416669 1.00 ACE (0.51) ACESLC7A5TAAR1SLC6A2FOLH1
SCHEMBL7637685 0.87 ESR1 (0.56) ACESLC7A5TAAR1SLC6A2FOLH1
SCHEMBL8231892 0.87 ESR1 (0.56) ACESLC7A5TAAR1SLC6A2FOLH1
SCHEMBL14942927 0.87 ESR1 (0.56) ACESLC7A5TAAR1SLC6A2FOLH1
SCHEMBL18125888 0.86 TDP1 (0.43) ACE
SCHEMBL12324615 0.86 TDP1 (0.43) ACE
SCHEMBL24286177 0.86 CA2 (0.43) ACECA2MME
SCHEMBL9886029 0.86 TDP1 (0.43) ACE
SCHEMBL18493175 0.85 ACE (0.48) ACESLC7A5TAAR1SLC6A2FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022143-A1 Cyclic Peptide Inhibitors of IL-23 JANSSEN PHARMACEUTICA NV (BE) 2026-01-22 US disclosed
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2025-12-02 US disclosed
US-20240352073-A1 BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN BIOTECH INC (US) 2024-10-24 US disclosed
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 US disclosed
WO-2021217019-A1 RAS INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022143-A1 Cyclic Peptide Inhibitors of IL-23 IL23R, IL17A, IL36G ACE 2261/4885SLC7A5 1263/4885TAAR1 3019/4885
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 ACE 839/4885SLC7A5 1032/4885TAAR1 282/4885
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 ACE 836/4885SLC7A5 1044/4885TAAR1 271/4885
US-20240352073-A1 BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR IL23R, IL1RN, IL17A ACE 1092/4885SLC7A5 1924/4885TAAR1 883/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 ACE 839/4885SLC7A5 1032/4885TAAR1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.